Sage's postpartum depression candidate gets Priority Review

Sage Therapeutics Inc. (NASDAQ:SAGE) said FDA accepted and granted Priority

Read the full 109 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE